AstraZeneca has decided to discontinue one of its midstage cancer drugs—mTOR inhibitor vistusertib—despite reporting encouraging clinical data earlier in the year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,